Clinical trials
Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma clinical trials
Below are recruiting relapsed or refractory b-cell non-hodgkin lymphoma clinical trials, each written for real people, not researchers. We’re tracking 1,759 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07028112Recruiting
Iron and liver health after stem cell transplant
This study looks at how too much iron in the body (from past transfusions) affects the liver in people who had a stem cell transplant at least 10 years ago. It will help doctors understand who needs special monitoring for liver problems.
ParisAges 18 years+ - NCT07067255RecruitingPhase 1/Phase 2
Sequential CAR-T cells for advanced ovarian cancer with CD146 and GPC3
This trial tests a new type of immunotherapy called CAR-T cells that are designed to attack ovarian cancer cells that have two specific markers (CD146 and GPC3). It is for people with advanced ovarian cancer who have already tried standard treatments like platinum-based chemotherapy and need new options.
Beijing, Beijing MunicipalityAges 21–90 - NCT07075328RecruitingPhase 1/Phase 2
Study of OJP-001 for adult T-cell leukemia/lymphoma
This trial tests a new drug called OJP-001 for people with adult T-cell leukemia/lymphoma (ATL) that has come back or not responded to other treatments. The goal is to see if this drug can help control the disease.
Fukuoka, FukuokaAges 20–85 - NCT07075510RecruitingPhase 1/Phase 2
Comparing Daratumumab injection in thigh vs. abdomen for plasma cell disorders
This trial is for people with multiple myeloma or AL amyloidosis who are about to start treatment with a drug called daratumumab. It compares two places to inject the medicine (thigh vs. abdomen) to see which works better and is more comfortable.
Baltimore, MarylandAges 18 years+ - NCT07104721RecruitingPhase 1
YTS109 cell therapy for severe autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity in conditions like lupus, Sjögren's syndrome, and others.
Hefei, AnhuiAges 18–65 - NCT07123519RecruitingPhase 1
YTS109 cell therapy for hard-to-treat autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with certain severe autoimmune diseases that have not responded to standard treatments, such as lupus, Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, vasculitis, and antiphospholipid syndrome. The goal is to see if it can safely reduce disease activity.
TianjinAges 18–65 - NCT07126782RecruitingEarly Phase 1
Gene-edited immune cells for AML after transplant
This trial tests a type of immune cell called gamma-delta T cells in people with acute myeloid leukemia who still have minimal residual disease after a stem cell transplant. The goal is to see if these cells can clear the remaining leukemia cells safely and effectively.
BeijingAges 18 years+ - NCT07144020RecruitingEarly Phase 1
Donor CAR-T cells for relapsed or refractory AML
This trial tests a new treatment using your donor's immune cells that are engineered to find and attack cancer cells with a specific marker called CD117. It's for people with acute myeloid leukemia (AML) that has come back or not responded to standard treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT07193667Recruiting
CAR-T therapy for autoimmune diseases
This study tests a type of immunotherapy called CAR-T for people with certain autoimmune diseases that have not responded to standard treatments. It aims to see if this cell therapy can calm the overactive immune system.
Shenyang, LiaoningAges 18–65 - NCT07222735RecruitingPhase 1
CAR T cells and radiation for children with sarcoma
This trial tests a combination of targeted radiation and special immune cells (CAR T cells) for children and young adults whose bone or soft tissue sarcoma has come back or not responded to standard treatments. The CAR T cells are made from your own blood cells and are designed to attack a protein called B7-H3 found on the sarcoma cells.
Memphis, TennesseeAges Up to 21 years - NCT07225361RecruitingPhase 4
Ublituximab for early relapsing multiple sclerosis
This study tests ublituximab (Briumvi), a treatment given as an infusion, for people recently diagnosed with relapsing MS. The goal is to see if starting this treatment early helps control MS better.
Chicago, IllinoisAges 18–70 - NCT07228624RecruitingPhase 2
Ruxolitinib before, during, and after transplant for myelofibrosis
This trial tests whether taking the drug ruxolitinib before, during, and after a stem cell transplant helps older patients with myelofibrosis or certain related blood disorders. The goal is to see if this approach can improve transplant success and reduce side effects.
Seattle, WashingtonAges 18–75 - NCT07236762RecruitingPhase 1
YTS109 cell therapy for severe autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases like lupus, Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, vasculitis, and antiphospholipid syndrome. It's for those whose disease hasn't improved with standard treatments.
BengbuAges 18–65 - NCT07236801RecruitingPhase 1
Cell therapy for hard-to-treat autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with several autoimmune diseases that have not improved with standard medications. It aims to see if this treatment can help control the disease when other treatments have failed.
Xuzhou, JiangsuAges 18–65 - NCT07246096RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.
ShanghaiAges 18–70 - NCT06234904RecruitingPhase 1
IBR733 cell therapy for acute myeloid leukemia
This trial tests a new cell treatment called IBR733 for people with acute myeloid leukemia (AML) that has come back or not responded to other treatments. The goal is to see if it is safe and helps fight the leukemia.
Suzhou, JiangsuAges 18–74 - NCT05359653RecruitingPhase 1/Phase 2
Clemastine to study MRI changes in relapsing MS
This early-phase study tests whether clemastine (a drug being studied for “myelin repair”) changes how MS looks on special MRI scans. It may help researchers understand if the treatment supports restoring nerve covering in people with relapsing-remitting MS.
San Francisco, CaliforniaAges 18–55 - NCT07292480Recruiting
Monthly NfL monitoring for relapsing-remitting MS
This trial tests whether monthly blood tests for a nerve protein (NfL) can detect hidden disease activity in people with relapsing-remitting multiple sclerosis (RRMS) who are on certain first-line treatments. It aims to find out if this monitoring helps catch early signs of active disease before symptoms appear.
NiceAges 18–55 - NCT07319897RecruitingPhase 2/Phase 3
BCMA PET scan for multiple myeloma imaging
This trial tests a new type of PET scan that uses a radioactive tracer (68Ga-BCMA) to find active multiple myeloma cells in your body. It may help doctors better detect and monitor the disease.
Beijing, Beijing MunicipalityAges 18–80 - NCT07320235RecruitingPhase 1
Combination treatment for relapsed AML
This trial tests a new combination of drugs for people whose acute myeloid leukemia (AML) has come back or not responded after at least one prior treatment, and who have no other standard options. The goal is to see if adding imetelstat to other therapies can help.
New York, New YorkAges 18 years+ - NCT07321093RecruitingPhase 3
A study of BCD-281 for relapsing-remitting MS
This trial tests a new medicine called BCD-281 for people with relapsing-remitting multiple sclerosis (RRMS). It aims to see if the drug can reduce relapses and improve disease control.
Nizhny NovgorodAges 18–55 - NCT07328425RecruitingPhase 2
A study of lurbinectedin and irinotecan for advanced DSRCT
This trial tests a combination of two chemotherapy drugs (lurbinectedin and irinotecan) for people with desmoplastic small round cell tumor (DSRCT) that has spread or cannot be removed by surgery. It is for patients whose cancer has gotten worse after at least one prior treatment.
Candiolo, TorinoAges 15 years+ - NCT07334301RecruitingPhase 1/Phase 2
Combination treatments for relapsed high-risk neuroblastoma
This trial is testing different combinations of medicines for children with high-risk neuroblastoma that has come back. It has two paths: one for children whose disease has relapsed only once, and another for those whose disease has come back more than once. The goal is to find which treatments work best.
SydneyAges 1 year+ - NCT02048332RecruitingPhase 1/Phase 2
Donor immune cells for preventing infections after stem cell transplant
This trial studies donor-made immune cells (T-cells) given after a stem cell transplant to help your body fight infections. It aims to test how safe the treatment is and whether it supports the immune system in the months after transplant.
Akron, OhioAges 4 weeks+
Hear when a new Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory b-cell non-hodgkin lymphoma?
- Yes. Clin2 currently lists 1,759 recruiting relapsed or refractory b-cell non-hodgkin lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory b-cell non-hodgkin lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory b-cell non-hodgkin lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.